PROCEPT BioRobotics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 27, 2024 at 04:07 pm EST
Share
PROCEPT BioRobotics Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 43.58 million compared to USD 23.78 million a year ago. Net loss was USD 27.5 million compared to USD 28.17 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.63 a year ago.
For the full year, sales was USD 136.19 million compared to USD 75.01 million a year ago. Net loss was USD 105.9 million compared to USD 87.15 million a year ago. Basic loss per share from continuing operations was USD 2.24 compared to USD 1.96 a year ago.
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
PROCEPT BIOROBOTICS CORPORATION 
